CytomX Therapeutics Inc expected to post a loss of 3 cents a share - Earnings Preview

CytomX Therapeutics

08/03/2024 20:17

* CytomX Therapeutics Inc  CTMX.OQ   CTMX.O  is expected
to show a
rise in quarterly revenue when it reports  results on March 11
for the period ending December 31 2023
    * The South San Francisco California-based  company is
expected to
report a 2,124.4% increase in revenue to $21.043 million from
$946 thousand a year ago, according to the mean estimate from 7
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for CytomX Therapeutics Inc
is for
a loss of 3 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 5
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for CytomX
Therapeutics Inc is $3.00​, above​ its last closing price
of $2.56. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.15       -0.19      0.04      Beat    121.2
 Jun. 30 2023  -0.18       -0.20      -0.02     Beat    90.2
 Mar. 31 2023  -0.12       -0.11      -0.05     Beat    52.7​
 Dec. 31 2022  -0.17       -0.24      -0.43     Missed  -82.5
 ​​Sep.        -0.29       -0.31      -0.35     Missed  -14.5
 30 2022                                                
 Jun. 30 2022  -0.36       -0.36      -0.37     Missed  -2.8​
 Mar. 31 2022  -0.38       -0.36      -0.37     Missed  -1.8
 Dec. 31 2021  -0.14       -0.28      -0.40     Missed  -41.7
 This summary was machine generated March 8 at 20:17 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)